Analyst Rating Update on Agenus (AGEN)

Agenus (AGEN) : 4 analysts are covering Agenus (AGEN) and their average rating on the stock is 1, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 1, which recommends a Strong Buy affirms that they expect a large upside in the stock from the current levels.

Agenus (AGEN) : The highest short term price target forecast on Agenus (AGEN) is $10 and the lowest target price is $7. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $8 with a standard deviation of $1.73.

For the current week, the company shares have a recommendation consensus of Buy.


Agenus (NASDAQ:AGEN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.50 and $5.48 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.85. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.75, notching a gain of 3.60% for the day. The total traded volume was 1,132,827 . The stock had closed at $5.55 on the previous day.

Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *